DELVIFARMA SL
Company details
- Active NIF/CIF: B91788067
-
-
-
-
Address: C/ ALVAREZ QUINTERO 7 - VESTIBULO 5-2º (SEVILLA)
-
-
Featured products:
More information on DELVIFARMA SL
-
18/04/2011 | BORME act no.: 173372 | Register: SEVILLAAmpliación de capital
-
18/04/2011 | BORME act no.: 173372 | Register: SEVILLAModificaciones estatutarias
-
05/11/2010 | BORME act no.: 999379 | Register: SEVILLADepósito de cuentas anuales (Octubre de 2010)
-
28/05/2010 | BORME act no.: 214844 | Register: SEVILLAAmpliación de capital
-
28/05/2010 | BORME act no.: 214844 | Register: SEVILLAModificaciones estatutarias
-
13/10/2009 | BORME act no.: 646853 | Register: SEVILLADepósito de cuentas anuales (Septiembre de 2009)
-
03/02/2009 | BORME act no.: 59229 | Register: SEVILLAConstitución
-
03/02/2009 | BORME act no.: 59229 | Register: SEVILLANombramientos
Other information
The CIF of DELVIFARMA SL is B91788067, and its status in the business field is active. The company's economic activity is classified under CNAE 4646 - Comercio al por mayor de productos farmacéuticos. Additionally, its SIC code 5199 - Productos diversos perecederos also identifies it. DELVIFARMA SL has a team of Between 10 and 49 employees and records an annual turnover of less than 2 million euros. The company is registered in the Mercantile Registry of Sevilla, with a total of 2 executive positions. The last announcement in Borme was published on 18/04/2011, and its last submission of ordinary annual accounts corresponds to the year -. To obtain contact information for DELVIFARMA SL, such as phone number, address, or website, you can visit the Company Data module. If you wish to obtain more information about DELVIFARMA SL, you can review some of our available financial reports, the company's Annual Accounts, or check its default incidents in the RAI delinquency file. The financial, business, and legal information provided for DELVIFARMA SL comes from official sources and is up to date as of today.
Do you want to know more about DELVIFARMA SL??
Find out more about this company by consulting these reports: